Impaired Langerhans cell migration in psoriasis

Journal of Experimental Medicine

Volumn 203, Issue 4, 2006, Pages 953-960

  Cumberbatch, Marie ^a   Singh, Minal ^b   Dearman, Rebecca J ^a   Young, Helen S ^b   Kimber, Ian ^a   Griffiths, Christopher E M ^b  

^a JEALOTT S HILL INTERNATIONAL RESEARCH CENTRE   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; LANGERHANS CELL; MALE; MOBILIZATION; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; STIMULUS RESPONSE; TURNOVER TIME;

ADOLESCENT; ADULT; CELL COUNT; CELL MOVEMENT; CELL SEPARATION; CYTOKINES; FEMALE; HUMANS; LANGERHANS CELLS; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1 TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SKIN;

EID: 33645849838     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20052367     Document Type: Article

References (41)

1. Griffiths, C.E.M., R.D.R. Camp, and J.N.W.N. Barker. 2004. Psoriasis. In Rook's Textbook of Dermatology, seventh edition. D.A. Burns, S.M. Breathnach, N.H. Cox, and C.E.M. Griffiths, editors. Blackwell Publishing, Oxford, UK. 35.1-35.69.
2. Fortune, D.G., C.J. Main, T.M. O'Sullivan, and C.E.M. Griffiths. 1997. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br. J. Dermatol. 137:755-760.
3. Capon, F., R.C. Trembath, and J.N.W.N. Barker. 2004. An update on the genetics of psoriasis. Dermatol. Clin. 22:339-347.
4. Chamian, F., and J.G. Krueger. 2004. Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr. Opin. Rheumatol. 16:331-337.
5. Davison, S.C., A. Ballsdon, M.H. Allen, and J.N.W.N. Barker. 2001. Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques. Exp. Dermatol. 10:280-285.
6. Nickoloff, B.J., G.D. Karabin, J.N.W.N. Barker, C.E.M. Griffiths, V. Sarma, R.S. Mitra, J.T. Elder, S.L. Kunkel, and V.M. Dixit. 1991. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am. J. Pathol. 138:129-140.
7. Ellis, C.N., M.S. Fradin, J.M. Messana, M.D. Brown, M.T. Siegel, A.H. Hartley, L.C. Rocher, S. Wheeler, T.A. Hamilton, T.G. Parish, et al. 1991. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N. Engl. J. Med. 324:277-284.
8. Gottlieb, S.L., N.S. Heftler, P. Gilleaudeau, R. Johnson, V.P. Vallat, J. Wolfe, A.B. Gottlieb, and J.G. Krueger. 1995. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1:442-447.
9. Gordon, K.B., K.A. Papp, T.K. Hamilton, P.A. Walicke, W. Dummer, N. Li, B.W. Bresnahan, and A. Menter, and Efalizumab Study Group. 2003. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 290:3073-3080.
10. Wrone-Smith, T., and B.J. Nickoloff. 1996. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 15:1695-1696.
11. Cumberbatch, M., R.J. Dearman, C.E.M. Griffiths, and I. Kimber. 2000. Langerhans cell migration. Clin. Exp. Dermatol. 25:413-418.
12. Griffiths, C.E.M., M. Cumberbatch, S.C. Tucker, R.J. Dearman, S. Andrew, D.R. Headon, and I. Kimber. 2001. Exogenous topical lactoferrin inhibits allergen-induced Langerhans cell migration and cutaneous inflammation in humans. Br. J. Dermatol. 144:715-725.
13. Cumberbatch, M., C.E.M. Griffiths, S.C. Tucker, R.J. Dearman, and I. Kimber. 1999. Tumour necrosis factor-α induces Langerhans cell migration in humans. Br. J. Dermatol. 141:192-200.
14. Cumberbatch, M., M. Bhushan, R.J. Dearman, I. Kimber, and C.E.M. Griffiths. 2003. IL-1β-induced Langerhans' cell migration and TNF-α production in human skin: regulation by lactoferrin. Clin. Exp. Immunol. 132:352-359.
15. Bieber, T., and O. Braun-Falco. 1989. Distribution of CD1a-positive cells in psoriatic skin during the evolution of the lesions. Acta Derm. Venereol. 69:175-178.
16. Ashworth, J., and R.M. Mackie. 1986. A quantitative analysis of the Langerhans cell in chronic plaque psoriasis. Clin. Exp. Dermatol. 11:594-599.
17. Moss, C., P.S. Friedmann, and S. Shuster. 1981. Impaired contact hypersensitivity in untreated psoriasis and the effects of photochemotherapy and dithranol/UV-B. Br. J. Dermatol. 105:503-508.
18. Henseler, T., and E. Christophers. 1995. Disease concomitance in psoriasis. J. Am. Acad. Dermatol. 32:982-986.
19. Cumberbatch, M., R.J. Dearman, and I. Kimber. 1999. Induction by tumour necrosis factor alpha of dose related changes in Langerhans cell frequency in mice. Arch. Dermatol. Res. 291:453-458.
20. Larregina, A., A. Morelli, E. Kolkowski, and L. Fainboim. 1996. Flow cytometric analysis of cytokine receptors on human Langerhans' cells. Changes observed after short-term culture. Immunology. 87:317-325.
21. Cumberbatch, M., and I. Kimber. 1995. Tumour necrosis factor-α is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitisation. Immunology. 84:31-35.
22. Cumberbatch, M., R.J. Dearman, and I. Kimber. 1997. Langerhans cells require signals from both tumour necrosis factor-α and interleukin-1β for migration. Immunology. 92:388-395.
23. Bhushan, M., M. Cumberbatch, R.J. Dearman, I. Kimber, and C.E.M. Griffiths. 2004. Exogenous interleukin-1β restores impaired Langerhans cell migration in aged skin. Br. J. Dermatol. 150:1217-1218.
24. Hammerberg, C., W.P. Arend, G.J. Fisher, L.S. Chan, A.E. Berger, J.S. Haskill, J.J. Voorhees, and K.D. Cooper. 1992. Interleukin-1 receptor antagonist in normal and psoriatic epidermis. J. Clin. Invest. 90:571-583.
25. Homey, B., M.C. Dieu-Nosjean, A. Wiesenborn, C. Massacrier, J.J. Pin, E. Oldham, D. Catron, M.E. Buchanan, A. Muller, R. deWaal Malefyt, et al. 2000. Up-regulation of macrophage inflammatory protein-3α/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 164:6621-6632.
26. Dieu-Nosjean, M.C., C. Massacrier, B. Homey, B. Vanbervliet, J.J. Pin, A. Vicari, S. Lebeque, C. Dezutter-Dambuyant, D. Schmitt, A. Zlotnik, and C. Caux. 2000. Macrophage inflammatory protein 3α is expressed at inflamed epithelial surface and is the most potent chemokine known in attracting Langerhans cell precursors. J. Exp. Med. 192:705-717.
27. Yawalkar, N., S. Karlen, R. Hunger, C.U. Brand, and L.R. Braathen. 1998. Expression of interleukin-12 is increased in psoriatic skin. J. Invest. Dermatol. 111:1053-1057.
28. Blumberg, H., D. Conklin, W.F. Xu, A. Grossmann, T. Brender, S. Carollo, M. Eagan, D. Foster, B.A. Haldeman, A. Hammond, et al. 2001. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell. 104:9-19.
29. van der Fits, L., L.I. van der Wel, J.D. Laman, E.P. Prens, and M.C.M. Verschuren. 2003. Psoriatic lesional skin exhibits an aberrant expression pattern of interferon regulatory factor-2 (IRF-2). J. Pathol. 199:107-114.
30. Elder, J.T., G.J. Fisher, P.B. Lindquist, G.L. Bennett, M.R. Pittelkow, R.J. Coffey Jr., L. Ellingsworth, R. Derynck, and J.J. Voorhees. 1989. Overexpression of transforming growth factor α in psoriatic epidermis. Science. 10:811-814.
31. Pastore, S., F. Mascia, F. Mariotti, C. Dattilo, and G. Girolomoni. 2004. Chemokine networks in inflammatory skin diseases. Eur. J. Dermatol. 14:203-218.
32. Nestle, F.O., C. Conrad, A. Tun-Kyi, B. Homey, M. Gombert, O. Boyman, G. Burg, Y.J. Liu, and M. Gilliet. 2005. Plasmacytoid pre-dendritic cells initiate psoriasis through interferon-α production. J. Exp. Med. 202:135-143.
33. Fujita, H., A. Asahina, Y. Tada, H. Fujiwara, and K. Tamaki. 2005. Type I interferons inhibit maturation and activation of mouse Langerhans cells. J. Invest. Dermatol. 125:126-133.
34. Zhou, X., J.G. Krueger, M.C. Kao, E. Lee, F. Du, A. Menter, W.H. Wong, and A.M. Bowcock. 2003. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol. Genomics. 13:69-78.
35. Nickoloff, B.J., and F.O. Nestle. 2004. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 113:1664-1678.
36. Angeli, V., J. Llodra, J.X. Rong, K. Satoh, S. Ishii, T. Shimizu, E.A. Fisher, and G.W. Randolph. 2004. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity. 21:561-574.
37. Kaplan, D.H., M.C. Jenison, S. Saeland, W.D. Shlomchik, and M.J. Shlomchik. 2005. Epidermal Langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity. 23:611-620.
38. Schiavoni, G., F. Mattei, P. Borghi, P. Sestili, M. Venditti, H.C. Morse III, F. Belardelli, and L. Gabriele. 2004. ICSBP is critically involved in the normal development and trafficking of Langerhans cells and dermal dendritic cells. Blood. 103:2221-2228.
39. Rhodes, L.E., G. Belgi, R. Parslew, L. McLoughlin, C.F. Clough, and P.S. Friedmann. 2001. Ultraviolet-B induced erythema is mediated by nitric oxide and prostaglandin in combination. J. Invest. Dermatol. 117:880-885.
40. Rhodes, L.E., J.A. Hashim, P.J. McLaughlin, and P.S. Friedmann. 1999. Blister fluid cytokines in cutaneous inflammatory disorders. Acta Derm. Venereol. 79:288-290.
41. Lowry, O.H., N.J. Rosenbrough, A.L. Farr, and R.J. Randall. 1951. Protein measurement with the Folin Phenol reagent. J. Biol. Chem. 193:265-275.